2-(4-methylphenyl)ethanol nitrate | 130226-77-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methylphenyl)ethanol nitrate
• 英文别名: 2-(4-Methylphenyl)ethyl nitrate
• CAS: 130226-77-6
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: UYIIPKYMVBTPFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(4-甲基苯基)乙醇 生成 2-(4-methylphenyl)ethanol nitrate
  参考文献：
  名称：

  Pharmaceutical composition having relaxing activity which contains a

  摘要：

  该发明涉及含有新型硝酸酯的药物组合物，发现它们对治疗缺血性心脏病、心力衰竭、心肌梗死和高血压有用。

  公开号：

  US05049694A1

文献信息

• The role of nitrate free radicals in the photochemical side-chain nitrooxylation of alkylbenzenes by cerium(IV) ammonium nitrate in acetonitrile
  作者：E. Baciocchi、I. Del Giacco、C. Rol、G.V. Sebastiani

  DOI：10.1016/s0040-4039(00)61933-0

  日期：1985.1

  It is suggested that the reactive species in the CAN-induced photochemical side-chain nitrooxylation of alkylbenzenes is the nitrate radical, which probably acts as one-electron oxidant.

  建议在CAN诱导的烷基苯的光化学侧链硝基氧化中的反应性物种是硝酸根，它可能起单电子氧化剂的作用。
• Nitrosated glutamic acid compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20070037821A1

  公开（公告）日：2007-02-15

  The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic acid compound, and, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (m) the targeted delivery of compounds and nitric oxide to organs, cells or tissues containing the enzyme gamma-glutamyl transpeptidase.

  该发明描述了新型的硝化谷氨酸化合物及其药学上可接受的盐，以及包含至少一种硝化谷氨酸化合物，和/或至少一种一氧化氮供体和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种硝化谷氨酸化合物，和/或至少一种一氧化氮供体化合物和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗心血管疾病、肾血管疾病、糖尿病、氧化应激引起的疾病、内皮功能障碍、内皮功能障碍引起的疾病、肝硬化、先兆子痫、骨质疏松症、肾病、γ-谷氨酰转移酶水平升高引起的疾病以及将化合物和一氧化氮有针对性地输送到含有γ-谷氨酰转移酶的器官、细胞或组织的方法。
• Pharmaceutical composition having relaxing activity which contains a nitrate ester as active substance
  申请人：CEDONA PHARMACEUTICALS B.V.

  公开号：EP0359335A2

  公开（公告）日：1990-03-21

  The invention relates to pharmaceutical compositions containing novel nitrate esters, of which it was found that they are useful for the treatment of ischemiatic heart diseases, decompensatio cordis, myocardial infarct­ion, hypertension, etc., said novel nitrate esters meet formula 1 as defined in claim 1.

  本发明涉及含有新型硝酸酯的药物组合物，发现这些药物组合物可用于治疗异质性心脏病、心肌缺血、心肌梗塞、高血压等，所述新型硝酸酯符合权利要求1中定义的式1。
• [DE] VERWENDUNG VON SUBSTITUIERTEN ALKYLNITRATEN ZUR BEHANDLUNG DES KRANKHAFT ERHÖHTEN AUGENINNENDRUCKES<br/>[EN] USE OF SUBSTITUTED ALKYL NITRATES FOR THE TREATMENT OF PATHOLOGICALLY INCREASED INTRA-OCULAR PRESSURE<br/>[FR] UTILISATION DE NITRATES D'ALKYLE SUBSTITUES POUR LE TRAITEMENT D'UN ACCROISSEMENT PATHOLOGIQUE DE LA PRESSION INTRA-OCULAIRE
  申请人：BYK NEDERLAND BV

  公开号：WO1994021248A1

  公开（公告）日：1994-09-29

  (DE) Die Erfindung betrifft die Verwendung von Verbindungen der Formel (I), worin R1 und R2 die in der Beschreibung angegebenen Bedeutungen haben, und ihren pharmakologisch verträglichen Salzen zur Herstellung von Arzneimitteln für die Behandlung des krankhaft erhöhten Augeninnendruckes.(EN) The invention pertains to the use of compounds of formula (I) wherein R1 and R2 stand for the constituents indicated in the description, and of their pharmacologically tolerable salts in the preparation of medicines for the treatment of pathologically increased intra-ocular pressure.(FR) L'invention concerne l'utilisation de composés de formule (I), dans laquelle R1 et R2 ont les notations données dans la description, et de leurs sels pharmacologiquement tolérables pour la fabrication de médicaments destinés au traitement d'un accroissement pathologique de la pression intra-oculaire.

  该发明涉及使用形式为(I)的化合物及其 pharmakologically tolerable 盐，以制备用于治疗视力增高的药物。
• VERWENDUNG VON SUBSTITUIERTEN ALKYLNITRATEN ZUR BEHANDLUNG DES KRANKHAFT ERHÖHTEN AUGENINNENDRUCKES
  申请人：BYK NEDERLAND BV

  公开号：EP0689435A1

  公开（公告）日：1996-01-03